A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 09 Jul 2022
At a glance
- Drugs Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Elcelyx Therapeutics
- 12 Nov 2014 Planned primary completion date changed to 1 Nov 2013.
- 18 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 17 Sep 2013 Twelve week results are expected in October 2013 according to an Elcelyx media release.